Co-expression of neuregulins 1,2,3 and 4 in human breast cancer

Journal of Pathology

Volumn 203, Issue 2, 2004, Pages 672-680

  Dunn, Mariana ^a   Sinha, Prakash ^b   Campbell, Rebecca ^c   Blackburn, Edith ^a   Levinson, Neil ^d   Rampaul, Raj ^e   Bates, Tom ^b   Humphreys, Stephen ^f   Gullick, William J ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

^b WILLIAM HARVEY HOSPITAL   (United Kingdom)

^c OXFORD BROOKES UNIVERSITY   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^f Preston Hall Hospital   (United Kingdom)

Author keywords

Breast cancer; Growth factor; Growth factor receptor; Neuregulin; Tyrosine kinase

Indexed keywords

ISOPROTEIN; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR 1; NEU DIFFERENTIATION FACTOR 1 ALPHA; NEU DIFFERENTIATION FACTOR 1 BETA; NEU DIFFERENTIATION FACTOR 2; NEU DIFFERENTIATION FACTOR 2 ALPHA; NEU DIFFERENTIATION FACTOR 2 BETA; NEU DIFFERENTIATION FACTOR 3; NEU DIFFERENTIATION FACTOR 4; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MOLECULAR CLONING; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CLONING, MOLECULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; NEUREGULIN-1; NEUREGULINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 2642517107     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1561     Document Type: Article

References (36)

1. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14-30.
2. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett 1999; 447: 227-231.
3. Aguilar Z, Slamon DJ. The transmembrane heregulin precursor is functionally active. J Biol Chem 2001; 276: 44 099-44 107.
4. Gilmore LMR, Macleod KG, McCaig A, et al. Neuregulin expression, function and signaling in human ovarian cancer cells. Clin Cancer Res 2002; 8: 3933-3942.
5. Fluge O, Akslen LA, Haugen DR, Varhaug JE, Lillehaug JR. Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas. Int J Cancer 2000; 87: 763-770.
6. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997; 15: 2705-2716.
7. Gullick WJ. c-erbB-4/HER4: friend or foe? J Pathol 2003; 200: 279-281.
8. Williams EE, Trout LJ, Gallo RM, et al. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 2003; 192: 67-74.
9. Sartor CI, Zhou H, Kozlowska E, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001; 21: 4265-4275.
10. Srinivasan R, Benton E, McCormick F, Gullick WJ. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta and Betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res 1999; 5: 2877-2883.
11. Raj F, Skinner A, Mahji U, et al. Heregulin alpha expression in locally advanced breast cancer. Breast 2001; 10: 41-45.
12. Visscher DW, Sarkar FH, Kasunic TC, Reddy KB. Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. Breast Cancer Res Treat 1997; 45: 75-80.
13. Leung HY, Weston J, Gullick WJ, Williams G. Potential autocrine loop between Heregulin-a and ERBB3 receptor in human prostatic adenocarcinoma. Br J Urol 1997; 79: 212-216.
14. Leverton KE, Gullick WJ. The type 1 family of growth factor receptors and their ligands in prostate cancer. In Endocrine Oncology, Ethier S (ed). Humana Press: Totowa, NJ 2000; 277-291.
15. Lyne JC, Melhem MF, Finley GG, et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997; 3: 21-30.
16. Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001; 58: 114-122.
17. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8: S19-26.
18. Hobbs SS, Coffing SL, Le AT, et al. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 2002; 21: 8442-8452.
19. Crovello CS, Lai C, Cantley LC, Carraway KL 3rd. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. J Biol Chem 1998; 273: 26 954-26 961.
20. Nakano N, Higashiyama S, Kajihara K, et al. NTAKalpha and beta isoforms stimulate breast tumor cell growth by means of different receptor combinations. J Biochem (Tokyo) 200; 127: 925-930.
21. Ring HZ, Chang H, Guilbot A, Brice A, LeGuern E, Francke U. The human neuregulin-2 (NRG2) gene: cloning, mapping and evaluation as a candidate for the autosomal recessive form of Charcot-Marie-Tooth disease linked to 5q. Hum Genet 1999; 104: 326-332.
22. Higashiyama S, Horikawa M, Yamada K, et al. A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J Biochem (Tokyo) 1997; 122: 675-680.
23. Chang H, Riese DJ 2nd, Gilbert W, Stern DF, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 1997; 387: 509-512.
24. Carraway KL 3rd, Weber JL, Unger MJ, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997; 387: 512-516.
25. Busfield SJ, Michnick DA, Chickering TW, et al. Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol 1997; 17: 4007-4014.
26. Yamada K, Ichino N, Nishii K, et al. Characterization of the human NTAK gene structure and distribution of the isoforms for rat NTAK mRNA. Gene 2000; 255: 15-24.
27. Zhang D, Sliwkowski MX, Mark M, et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 1997; 94: 9562-9567.
28. Harari D, Tzahar E, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999; 18: 2681-2689.
29. Rajkumar T, Gullick WJ. The production of antibodies to growth factor receptors using synthetic peptides as immunogens. In Clinical Gene Analysis and Manipulation, JA Jankowski (ed), Cambridge University Press: Cambridge, UK, 1996; 99-110.
30. Rajkumar T, Stamp GWH, Pandha HS, Waxman J, Gullick WJ. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB-2 and c-erbB-3 in bladder cancer. J Pathol 1996; 179: 381-385.
31. Rajkumar T, Stamp GWH, Hughes CM, Gullick WJ. c-erbB-3 expression in ovarian cancer. J Clin Pathol: Mol Pathol 1996; 49: 199-202.
32. Prato Murphy ML, Meyer RF, Mebus C, Shudel AA, Rodriguez M. Analysis of sites of foot-and-mouth disease virus persistence in carrier cattle. Arch Virol 1994; 136: 299-307.
33. Prato Murphy ML, Forsyth MA, Belsham GJ, Salt JS. Localization of foot-and-mouth disease virus RNA by in situ hybridization within bovine tissues. Virus Res 1999; 62: 67-76.
34. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Expl Cell Res 2003; 284: 31-53.
35. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003: 11: 507-517.
36. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.